It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
The company will review FDA's response and decide on appropriate next steps soon.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
Subscribe To Our Newsletter & Stay Updated
